Global disease experts say little is known about China's experience with long-term COVID effects thought to have afflicted millions with debilitating fatigue, brain fog and other symptoms
EU starts real-time review of AstraZeneca COVID-19 antibody cocktail
Europe's drug regulator said on Thursday it had started a real-time review of the antibody-based COVID-19 therapy developed by AstraZeneca, roughly a week after the Anglo-Swedish drugmaker sought emergency approval from US authorities.
Published : 14 Oct 2021, 12:52 PM
Updated : 14 Oct 2021, 12:52 PM
The decision to begin the assessment by the human medicines committee of the European Medicines Agency (EMA) was based on early results from clinical studies, the regulator said in a statement https://www.ema.europa.eu/en/news/ema-starts-rolling-review-evusheld-tixagevimab-cilgavimab, without specifying when a conclusion was expected.
The medicine, the first protective shot other than vaccines against COVID-19, has proven to work in the non-infected and was also shown to save lives and prevent severe disease when given as treatment within a week of first symptoms.
"EMA will evaluate more data on the quality, safety and effectiveness of the medicine as they become available," the watchdog said, adding that the rolling review would continue until AstraZeneca submits a formal application for approval.
RELATED STORIES
The demonstrations helped to end COVID restrictions but failed to achieve lasting political change, six participants based in China and overseas say
The agency seeks details on an increase in respiratory illnesses and reported clusters of pneumonia in children, which its China office called a ‘routine’ check
The inquiry is examining the government's response to the coronavirus pandemic that shut large sections of the economy and killed more than 220,000 people in Britain
